Balance Sheet
Cash Flow Statement
AmortizationAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Ascendis Pharma A (ASND) over the last 12 years, with Q4 2025 value amounting to $85.4 million.

  • Ascendis Pharma A's Cash from Operations rose 19172.39% to $85.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $64.6 million, marking a year-over-year increase of 11950.56%. This contributed to the annual value of $60.9 million for FY2025, which is 11861.52% up from last year.
  • As of Q4 2025, Ascendis Pharma A's Cash from Operations stood at $85.4 million, which was up 19172.39% from $2.5 million recorded in Q3 2025.
  • Over the past 5 years, Ascendis Pharma A's Cash from Operations peaked at $85.4 million during Q4 2025, and registered a low of -$166.7 million during Q2 2023.
  • Moreover, its 5-year median value for Cash from Operations was -$105.0 million (2022), whereas its average is -$89.6 million.
  • As far as peak fluctuations go, Ascendis Pharma A's Cash from Operations crashed by 12249.03% in 2021, and later soared by 19172.39% in 2025.
  • Quarter analysis of 5 years shows Ascendis Pharma A's Cash from Operations stood at -$143.4 million in 2021, then dropped by 0.83% to -$144.6 million in 2022, then soared by 68.39% to -$45.7 million in 2023, then tumbled by 103.86% to -$93.2 million in 2024, then soared by 191.72% to $85.4 million in 2025.
  • Its last three reported values are $85.4 million in Q4 2025, $2.5 million for Q3 2025, and -$8.3 million during Q2 2025.